We are delighted to announce that four abstracts submitted by Research Partnership have been selected by The Professional Society for Health Economics and Outcomes Research for poster presentations at the ISPOR Europe 2023 conference, 12-15 November in Copenhagen, Denmark. Find out more about each of our posters below.
COVID-19: Do all patients who meet the EMA high-risk definition receive a prescription?
The European Medicines Agency (EMA) provides a framework to help identify patients most at-risk of disease progression with COVID-19 and ultimately who should receive COVID-19 treatment. Using Research Partnership’s 2022-2023 Therapy Watch COVID-19 Europe5 (France, Germany, Italy, Spain, UK) data, the objective of this study was to examine how closely EMA guidelines are followed in patients indicated to receive prescription (Rx) for COVID-19 treatment.
The experience of patients living with multiple myeloma: unmet needs associated with diagnosis, treatment, and living with the condition
Conducted in partnership with Sanofi Pharmaceuticals, this study explores patients’ experience of living with newly diagnosed multiple myeloma (NDMM), focusing on their perceived unmet needs at diagnosis, treatment, and care. A 30-minute online survey was conducted among actively treated transplant eligible (T-e) and transplant ineligible (T-ie) NDMM patients from France, Germany, Italy, Russia, Spain, UK, and US was conducted (June–December 2021). Patients’ experiences of diagnosis and treatment initiation, the physical and psychological burden of living with NDMM, and the perception of caregiver burden were documented.
Perceptions of current policy approaches to address antimicrobial resistance in Europe
Antimicrobial resistance (AMR) is one of the top 10 threats to global health, according to the World Health Organization (WHO). The magnitude of the issue was demonstrated in a WHO global surveillance report in 2014, however it is only in recent years that policymakers have developed and implemented policies to address AMR. The objective of this research was to explore payers’ perceptions of the impact of initiatives employed to address AMR, specifically Germany’s exceptional P&R pathway for antimicrobials and the UK’s innovative subscription model.
An evaluation of the reimbursement status of CAR-T cell therapies in the EU-4 and UK
Since 2018, six CAR-T cell therapies have obtained EU and UK marketing authorization. This research examines HTA body evaluations of the main clinical package and its impact on HTA ratings, where applicable, and reimbursement status on the six commercialized CAR-Ts in blood cancers in EU-4 and England. Primary research was conducted with 12 payers/proxies with advanced therapy.
If you’re planning to attend the conference and would like to meet with our thought leaders, contact us today to schedule a meeting.
